Consolidation of Contrast Agent Sales and Termination of the Sales Partnership
First written in FY2018-Q1. 1 of 3 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2018-Q3.
No other company in this theme has enough history to compare yet.
- FY2018-Q3AchievedAnnual report
「Sales of the nonionic urinary tract and vascular contrast agent Oypalomin Injection, the nonionic contrast agent Iopark Injection, and other products previously jointly sold with KONICA MINOLTA,INC. have been successfully consolidated under our company. In addition, as stated in the disclosure issued on 2 February 2018, we have agreed to terminate the license agreement with ゲルベ・ジャパン株式会社.」
States that sales of products jointly sold with KONICA MINOLTA,INC. have been fully consolidated under our company and confirms that agreement has been reached to terminate the license agreement with ゲルベ・ジャパン. - FY2018-Q2AdvancedAnnual report
「The contracts terminated upon expiration of their contractual terms are as follows.」
In connection with the agreement disclosed in the previous quarter to consolidate contrast agent sales under one distributor and the agreement to terminate the license agreement with ゲルベ・ジャパン, states that the sales agreement with KONICA MINOLTA,INC. for the urinary tract and vascular contrast agent Oypalomin ended upon expiration of its contractual term on 31 March 2018. - FY2018-Q1First statedAnnual report
「We reached an agreement to consolidate under our company, the manufacturer and marketing authorization holder, the sales of all contrast agents previously sold by KONICA MINOLTA,INC. As stated in the disclosure issued on the same day, titled “Termination of the partnership for sales of the nonionic contrast agent Optiray Injection, the cyclic MRI contrast agent Magnescope Intravenous Injection, and the lymphatic and hysterosalpingography contrast agent LIPIODOL Injection,” we also agreed on the same date to terminate the license agreement with ゲルベ・ジャパン株式会社.」
For the first time, describes the agreement dated 2 February 2018 to consolidate under our company the sales of contrast agents previously sold by KONICA MINOLTA,INC., and the agreement to terminate the license agreement with ゲルベ・ジャパン.